18F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer

Patent metadata

Field	Value
Publication number	US-10815200-B2
Application number	US-201815915978-A
Country	US
Kind code	B2
Filing date	Mar 8, 2018
Priority date	Sep 30, 2015
Publication date	Oct 27, 2020
Grant date	Oct 27, 2020

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.

First claim

The invention claimed is:

1. A compound of Formula I:

with:

i, j
0, 1

m
1-5

n
0-3

R
H, CH 3

AS
Natural or non-natural amino acid

Z:
—CO 2 H, —SO 2 H, —SO 3 H, —SO 4 H, —PO 2 H, —PO 3 H, —PO 4 H 2

X:
Naphthyl, Phenyl, Biphenyl, Indolyl (═2,3-benzopyrrolyl),

Benzothiazolyl, Quinoyl

Y:
Aryl, Alkylaryl, Cyclopentyl, Cyclohexyl, Cycloheptyl,

N-Piperidyl and N-methylated Piperidyl salt

18 F-Tag:

With:

x = 1-5

Carboydrate:

Assignees

• Deutsches Krebsforsch
• Univ Heidelberg Ruprecht Karls

Inventors

• Cardinale Jens
• Schaefer Martin
• Kopka Klaus
• Eder Matthias
• Bauder-Wuest Ulrike
• Eisenhut Michael
• Benesova Martina
• Haberkorn Uwe
• Giesel Frederik L

Classifications

• G01N33/57555

  of the prostate · CPC title

• G01N33/68

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title

• C07K7/02

  Linear peptides containing at least one abnormal peptide link · CPC title

• C07D213/61 Primary

  Halogen atoms or nitro radicals · CPC title

• A61K38/03

  Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof · CPC title